logo-loader

Co-Diagnostics earns Buy rating, $5 price target from Maxim after releasing coronavirus test

Published: 15:00 18 Feb 2020 EST

Sprouts growing from stacks of quarters leading to a jar of quarters
Maxim tagged the company with a Buy rating and increased its price target to $5

Co-Diagnostics Inc (NASDAQ:CODX) has caught the eye of analysts at Maxim Group as it moves ahead with its coronavirus diagnostic test. 

Maxim tagged the company with a Buy rating and increased its price target to $5 from $2, citing the speed at which Co-Diagnostics developed a detection test for the virus and its subsequent first sales in China.

“[The speed of development] highlights not just the platform's versatility, but also CDI's ability to produce tests in a time efficient manner as future threats emerge,” Maxim wrote. “We saw this with the Zika test and other viral tests from CDI.”

READ: Co-Diagnostics makes coronavirus diagnostic test available to researchers

The firm also noted Co-Diagnostics’ viral testing manufacturing facilities in India through its joint venture with CoSara Diagnostics.

Additionally, the Utah-based company recently boosted its balance sheet, raising roughly $15 million in two equity financings in January. The move “extended the company’s cash runway well into 2021, positioning it to unlock value in its commercial-stage infectious diseases testing platform.”

“We factor in dilution, roll our metrics forward to 2020, and lower the risk adjustment in our commercial model to 30%, from 75%,” Maxim wrote. “The net result raises our 12-month price target to $5 from $2.”

The coronavirus has killed at least 1,873 people and infected more than 72,000, according to CNN.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020